AFIAS HbA1c Neo
- UID
- IMP/IVD/2021/000365_ac63ddb8ed54f6df85533efac5147b46_c8ae8b80ab4146fa191763985fe3f2b0
- Device class
- Class B
- Brand name
- AFIAS Infliximab
- License holder
- BODITECH MED INDIA PRIVATE LIMITED
- Approving authority
- CDSCO
- Product information
- AFIAS HbA1c Neo is a fluorescence immunoassay (AFIAS Infliximab ) for the quantitative determination of HbA1c (AFIAS Infliximab ) in human whole blood. It is useful as an aid in management and monitoring of the long-term glycemic status in patients with diabetes mellitus. For in vitro diagnostic use only
AFIAS HbA1c Neo is a medical device registered with India's Central Drugs Standard Control Organization (CDSCO) under UID IMP/IVD/2021/000365_ac63ddb8ed54f6df85533efac5147b46_c8ae8b80ab4146fa191763985fe3f2b0. This device is marketed under the brand name AFIAS Infliximab . The license holder is BODITECH MED INDIA PRIVATE LIMITED, and it is classified as Device Class Class B. The approving authority is CDSCO.
This page provides comprehensive regulatory information including complete registration details, license holder information, device classification, and related products. Pure Global AI offers free access to 71,807+ India medical device registrations, helping global MedTech companies identify partners, analyze markets, and discover business opportunities efficiently.